Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced a $12.5 million registered direct offering of common stock at $2.00 per share. The offering is led by a strategic industry partner and select institutional investors.

The financing will be completed in two closings: an initial $8.5 million closing around July 18, 2025, and a second $4.0 million closing by November 25, 2025. Lake Street Capital Markets LLC serves as the exclusive placement agent. The proceeds will support product commercialization, research and development, and other corporate purposes.

Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Positive

• Strategic industry partner leading the investment demonstrates confidence in company
• Strengthens balance sheet with $12.5 million in new capital
• Two-phase closing structure provides staged funding approach
• Established market presence with over 150,000 patients treated globally

Negative

• Offering price of $2.00 per share may represent a discount to market price
• Share dilution impact on existing stockholders
• Second closing of $4.0 million subject to closing conditions
• Company requires additional funding for operations and commercialization

Insights

Investment Banking Analyst

Stereotaxis secured $12.5M financing led by strategic partner, strengthening balance sheet and supporting commercialization efforts during crucial growth period.

Stereotaxis (NYSE: STXS) has secured $12.5 million in new capital through a registered direct offering of common stock at $2.00 per share. The financing structure includes an initial closing of $8.5 million expected around July 18, with a second $4.0 million tranche scheduled by November 25. This staggered funding approach indicates cautious capital deployment while ensuring continued operational support.

The participation of a strategic industry partner alongside institutional investors is particularly noteworthy. While the partner remains unnamed, such strategic investments typically suggest potential commercial synergies beyond mere financial backing, possibly signaling future collaborative opportunities or validation of Stereotaxis's technology in the surgical robotics market.

The $2.00 per share pricing requires scrutiny in context of the company's recent trading patterns. The timing of this capital raise in what CEO David Fischel describes as a "milestone rich year" suggests the company is positioning to capitalize on near-term commercialization opportunities in the robotic surgery space, where sufficient capital is critical for market penetration against established competitors.

The proceeds allocation toward product commercialization and R&D aligns with the company's stage as a pioneer in endovascular robotic intervention. With over 150,000 patients treated using their technology, Stereotaxis appears to be in the scaling phase where additional capital can accelerate market adoption. However, this financing also implies the company isn't yet generating sufficient operational cash flow to fund these initiatives independently, necessitating dilution of existing shareholders.

• Led by Strategic Industry Partner and Select Institutional Investors
• Proceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy

ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors.

“We appreciate the support of our strategic partner and institutional investors in this offering, the proceeds from which will be used to accelerate product commercialization in this milestone rich year, as well as for research and development and other corporate purposes,” said David Fischel, Chairman and CEO.

The gross proceeds from the offering are expected to be approximately $12.5 million, before deducting placement agent’s fees and other offering expenses. An initial closing of approximately $8.5 million of the financing is expected to close on or about July 18, 2025 and a second closing of $4.0 million of the financing is scheduled to close on or before November 25, 2025, subject to customary closing conditions. Lake Street Capital Markets LLC is acting as the exclusive placement agent for the offering.

The offering is being made pursuant to a prospectus supplement to a shelf registration statement on Form S-3 (File No. 333-272102) that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective on June 6, 2023. A final prospectus supplement and accompanying prospectus forming part of such registration statement and containing additional information relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available,  by contacting Lake Street Capital Markets, LLC at 920 Second Avenue South, Unit 700, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

What is the size and price of Stereotaxis (STXS) July 2025 stock offering?

Stereotaxis announced a $12.5 million registered direct offering of common stock priced at $2.00 per share.

How will Stereotaxis (STXS) use the proceeds from the 2025 offering?

The proceeds will be used to accelerate product commercialization, support research and development, and for other corporate purposes.

When are the closing dates for the STXS 2025 stock offering?

The offering has two closings: $8.5 million around July 18, 2025, and $4.0 million by November 25, 2025.

Who is participating in the Stereotaxis (STXS) 2025 stock offering?

The offering is led by a strategic industry partner along with participation from select institutional investors.

How many patients have been treated with Stereotaxis technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.